Skip to content

News Releases

Date Title and Summary Additional Formats
Toggle Summary Mirati Therapeutics To Present Preclinical Data At 2016 American Association For Cancer Research Annual Meeting View HTML
Toggle Summary Mirati Therapeutics Announces Promotion Of Jamie A. Donadio To Chief Financial Officer View HTML
Toggle Summary Mirati Therapeutics Reports Fourth Quarter And Full Year 2015 Financial Results And Provides Business Update
Clinical Updates and Milestones Expected Across All Three Lead Programs During 2016
View HTML
Toggle Summary Mirati Therapeutics To Present At The Barclays Global Healthcare Conference View HTML
Toggle Summary Mirati Therapeutics Appoints Marcy Graham Vice President, Investor Relations and Corporate Communications View HTML
Toggle Summary Foundation Medicine And Mirati Therapeutics Collaborate To Develop A Companion Diagnostic For Glesatinib (MGCD265) In Non-Small Cell Lung Cancer (NSCLC)
Mirati Will Use FoundationOne® Genomic Profiling Assay to Identify Patients Most Likely to Benefit from Glesatinib
View HTML
Toggle Summary Guardant Health And Mirati Therapeutics Enter Into Collaboration On Glesatinib (MGCD265) In Non Small Cell Lung Cancer (NSCLC) Trial
Mirati to Use Guardant360® Circulating Tumor DNA Diagnostic Test for Glesatinib Patient Selection and Explore the Development of Guardant360® as a Companion Diagnostic Assay
View HTML
Toggle Summary Mirati Therapeutics Initiates Glesatinib (MGCD265) Phase 2 Trial In Non-Small Cell Lung Cancer (NSCLC)
Study Enrolling NSCLC Patients with Genetic Alterations of the MET GeneCompany Announces Proposed Generic Name of "Glesatinib" for MGCD265
View HTML
Toggle Summary Mirati Therapeutics Doses First Patient In Expansion Cohorts Of MGCD516 Phase 1b Trial In Genetically Selected Patients
Study Seeks to Establish a High Response Rate Among Cancer Patients with Specific Genetic Alterations that are Drivers of Tumor Growth
View HTML
Toggle Summary Mirati Therapeutics To Present At The Oppenheimer 26th Annual Healthcare Conference View HTML